Thienamycin (THM), the N-formimidoyl thienamycin derivative MK0787, and related carbapenem antibiotics were metabolized extensively in mice, rats, rabbits, dogs, rhesus monkeys, and chimpanzees. Urinary recovery of THM ranged from a low of 5% in dogs to 58% in rhesus monkeys. Renal clearance rates in dogs and chimpanzees were unusually low, less than glomerular filtration rates. The reduction in clearance of THM and MK0787 from plasma of rats and rabbits after ligation of renal arteries indicate that the kidneys are responsible for 35 and 92%, respectively, of metabolic drug clearance. Degradation was detected only in kidney homogenates. The enzyme activity was membrane bound and sensitive to inhibitors of Zn-metalloenzymes such as EDTA. A renal dipeptidase, dehydropeptidase-I (DHP-I), EC 3.4.13.11, was found to be responsible for the metabolism of the THM-class antibiotics, which exhibit a structural homology to dehydropeptides. A parallel increase in specific activity against THM and the substrate of DHP-I, glycyldehydrophenylalanine, was observed during solubilization and purification of the enzyme from porcine and human renal cortex. DHP-I was found to catalyze the hydrolysis of the beta-lactam ring in THM and MK0787. The products of the enzyme reaction were identical by high-powered liquid chromatography to their respective metabolites found in the urine. Nonbasic Nacylated THM and natural N-acylated carbapenems (epithienamycins and olivanic acids) were degraded 4-to 50-fold faster than THM when exposed to the enzymatic hydrolysis of DHP-I. Good correlations were obtained between the increased susceptibility of the carbapenem antibiotics to DHP-I as measured in the in vitro enzyme assay and the generally lower recoveries of active antibiotic in the urine of test animals. Despite this unusual degree of metabolism localized in the kidney, the plasma half-life of MK0787 and its efficacy against experimental systemic infections in animals remain satisfactory.
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Thienamycin (THM) and the N-formimidoyl thienamycin derivative MK0787 are members of a new class of structurally novel beta-lactam antibiotics, the carbapenems. Both are known for their high orders of activity against a broad spectrum of bacteria (11, 18, 19) . Their breadth of activity is in part attributable to resistance to attack by bacterial beta-lactamases (17) .
The low recovery of unaltered THM and MK0787 in the urine of laboratory animals suggested that these antibiotics are extensively metabolized. Incomplete urinary recoveries of cephalosporins such as cephalothin and cefotaxime have been ascribed to enzymatic (hepatic) cleavage of their acetylated side chains. In both instances, desacetyl metabolites with reduced antimicrobial activity and an intact beta-lactam are recovered in the urine of laboratory animals and in humans (6, 7, 9, 20) .
Biochemical studies presented in this report show that low urinary recoveries of THM and MK0787 result from the hydrolysis of the betalactam ring by the renal dipeptidase, dehydropeptidase-I (DHP-I), EC 3.4.13.11. A structural similarity exists between this new class of betalactam antibiotics and dehydropeptides as illustrated by the assay substrate, glycyldehydrophenylalanine (Gly-dh-Phe), shown in Fig. 1 Furtber purification of DHP-I, using immobilized Mertel of our enzyme inhibitor. Purification of DHP-I to apparent prepared from homogeneity as judged by gel electrophoresis and by incorporation using system no. 1 as described by Maurer [13] ) was the producing achieved by use of columns containing immobilized DHP-I inhibitors linked to Sepharose CL-6B resin rtex and liver (Pharmacia Fine Chemicals). The action of DHP-I ;, and pigs. centrifuged at gen bromide per ml of DMF) for 3 min in an ice bath oosely packed followed by washing of the resin with 1.0 liter of studies. Reac-distilled water. The activated resin was then immedi-)0 p,g/ml, in 75 ately added to the coupling solution consisting of 100 e homogenate ml of a selective inhibitor of DHP-I (5.0 mg/ml), the Z- Disposition studies in laboratory animals. Recovery of THM and MK0787 in urine was determined in the following laboratory animals: Mice (CD/1 Swiss albino, females, body weight, 20 g, n = 50 for each agent); rats (CDF, females, body weight, 150 g, n = 20 for each agent); rabbits (New Zealand white males, body weight, 3.0 to 3.5 kg, n = 10); dogs (beagles, males, body weight, 8 to 10 kg, n = 3 for each agent) and rhesus monkeys (Macaca mulatta, males, body weight, 5.0 to 8.0 kg, n = 3 for each agent). Antibiotic was administered in all studies as an intravenous bolus containing 5.0 mg/kg of body weight. Antibiotic activity was measured by the bioassay method of urine collected at 1-hour intervals over a 3-h period.
The pharmacokinetic parameters of THM and MK0787 were defined in a dog and a chimpanzee. At 40 min before drug administration, a male dog (body weight, 14.0 kg) received a 2.0-g bolus dose of creatinine subcutaneously. A constant infusion of dextrose, 5% in 0.9o saline, was administered at a rate of -2.0 ml min-1 to promote urine flow for the duration of the 3-h study. The chimpanzee, a male weighing 60 kg, received, 2 h before drug administration, a loading dose of inulin (50 mg/kg) and a constant intravenous infusion of 5% mannitol in 0.45% saline supplemented with 22 mg of inulin per ml and maintained at 3.0 ml min-' from -1.5 to +3 h. Antibiotic was administered as an intravenous bolus containing 5.0 mg/kg of body weight. Each subject was catheterized for urine recovery at successive 20-min intervals. Renal clearance rates of the antibiotics were calculated from the equation: renal clearance (milliliters per minute per kilogram) = urinary recovery (micrograms per kilogram of body weight)/area under plasma curve (micrograms per ml x minute). The antibiotic activity in plasma and urine specimens was determined by the bioassay method.
The effects of bilateral ligation of renal arteries on antibiotic plasma clearance rates were explored in two rats and two rabbits. Both test and control animals were laparotomized and held under ether (rats) or methoxyflurane (rabbits) anesthesia for the duration of the 3-to 4-h study. Drug (4.0 mg/kg) was administered subcutaneously to the rats (CDF males, body weight, 200 g) and as an intravenous bolus dose (5.0 mg/kg) to the rabbits (New Zealand white males, body weight, 3.0 to 3.5 kg).
Pharmacokinetic analysis. Parameters (see Table 2 ) for the dog and chimpanzee were derived by fitting plasma levels to a two-compartment open model, using the nonlinear regression program (COMPT) developed by Pfeffer (16) .
Bioassay for plasma and urinary recovery measurements. Measurements of antibiotic, THM, MK0787, and epithienamycins in plasma and urine were conducted on the same day that the specimens were collected by the following disk-diffusion bioassay, using Bacillus subtilis ML-32 (ATCC 12437) as the test organism. Plates were prepared by inoculation with 2.0 ml of 7.8 x 10' colony-forming units of MB-32 spores per ml to 100 ml of autoclaved brain heart infusion or Mueller-Hinton medium supplemented with 1.5% agar and cooled to 60°C. Ten milliliters of inoculated medium was then transferred into a petri dish (100 by 15 mm) on a level surface, distributed evenly, and allowed to harden. Plates were refrigerated until used (up to 24 h after preparation). Measured samples 20 RI of standard antibiotic solutions diluted in 50 mM MOPS buffer (pH 7.1) at concentrations of 0.25, 0.5, 1.0, and 2.0 ,ug/ml, were deposited onto paper disks (6.3-mm diameter). These standard disks were then placed on seeded agar plates (in triplicates) adjacent to disks bearing test samples appropriately diluted in 50 mM MOPS. The plates were incubated at 35°C overnight, and the zone diameters were measured and averaged for preparation of a standard curve; potencies of the test samples were calculated from the standard curve by conventional methods. Elution profiles of products from labeled MK0787 digested with DHP-I or by controlled acid hydrolysis were determined by HPLC (see Fig. 4A ).
Sample (ii) Add hydrolyzate. N-14C-labeled MK0787, (16 mM) was reacted in 0.1 N H2SO4 at 20°C for 10 min. Products were absorbed on Dowex-50x2, H+ and eluted by suspension of resin in water and titration with NaOH to pH 7.3.
({il) HPLC. Ten microliters of a mixture of the above digests was injected on a Waters Bondapak C18 column. The solvent was tetrabutylammonium-PO4 (5 mM), pH 7.1, pumped at 1.5 ml/min. Fractions of -0.5 ml (8 drops) were collected and counted.
An HPLC elution profile of labeled components in urine from a rabbit which received "4C-labeled MK0787 was determined. The urine sample was subsequently spiked with DHP-I digest of 3H-labeled MK0787 (see Fig. 4B ).
(lv) Urine. Pooled urine samples were collected over a 30-min period after rabbits were administered 14C-labeled MK0787 intravenously (5 mg/kg).
(v) HPLC conditions. Ten microliters of urine spiked with enzyme digest was injected on a Waters Bondapak C18 column. The solvent was 0.1 M (NH4)H2PO4, pumped at 1.5 ml/min. The component was tracked by using absorbance values at 313 nm and identified as MK0787, a mixture of two rotamers undergoing slow interconversion at pH 4.2.
RESULTS
Evidence for metabolism of THM. THM and its N-formimidoyl derivative, MK0787, underwent substantial species-variable metabolism as measured by the low urinary recovery of antibiotic (Table 1) . Pharmacokinetic parameters for THM and MK0787 in the dog and the chimpanzee are shown in Table 2 and Fig. 2 . Antibiotic renal clearance rates were unusually low and represented only a fraction of the glomerular filtration rate measured using creatine or inulin ( Table 2 ). The relative contribution of renal and extrarenal When DHP-I was partially purified (162-fold, based on Gly-dh-Phe substrate activity) from swine kidney, its specific activity was proportionately increased for THM (Table 4) . A further 32-fold purification was accomplished by using a column of DHP-I inhibitor immobilized on Seph- (Fig. 4A) , using a 3H-labeled (generally) sample of MK0787 for the DHP-I reaction and a "4C (side chain)-labeled preparation for acid hydrolysis. We conclude that DHP-I catalyzes beta-lactam hydrolysis by acting as a mammalian beta-lactamase on THM-type compounds.
Proof that DHP-I was responsible for the major fraction of antibiotic metabolism was provided by the chromatographic identity of an in vivo metabolite with DHP-I-hydrolyzed MK0787. Urine samples from rabbits receiving 14C-labeled MK0787 (labeled in the formate carbon of the formimidoyl group) were found to contain a single peak, in addition to intact MK0787, by HPLC ( Figure 4B ). It was shown that the in vivo metabolite coeluted with a 3H-labeled digest of MK0787 that had been treated previously with purified DHP-I. In rabbit urine collected over a 120-min period after intravenous administration, this metabolite, plus intact MK0787, accounted for 90 to 95% of total administered radioactivity.
Relative susceptibility of other carbapenems to DHP-I. All of the natural carbapenem antibiotics tested by us, as well as most semisynthetic derivatives of thienamycin, were metabolized more extensively than was either THM or MK0787 (Table 6 ). These compounds were also more susceptible to hydrolysis in vitro by DHP-I. There was good correlation between low urinary recovery and the extent of degradation of the carbapenem antibiotics by DHP-I.
DISCUSSION
The generally low urinary recoveries of THM and MK0787 observed in various laboratory species and in chimpanzees attest to the variable and sometimes extensive metabolic inactivation; whereas antibiotic in systemic circulation is spared from the rapid elimination that might be expected to result from metabolism of this magnitude. For example, the protective efficacy of these agents against experimental systemic infections in mice consistently exceeds that of nonmetabolized beta-lactam antibiotics and is in proportion to their relative in vitro antibacterial activities (11 Localization of metabolism in the kidney is strongly suggested by the finding that renal clearance rates in dogs and chimpanzees are only a fraction of the minimum value set by the glomerular filtration rates measured in those species. Although tubular reabsorption of antibiotic might be proposed to account for low renal clearance rates, this alternative would require that a proportionately larger fraction of antibiotic undergoes extrarenal metabolism. The magnitude by which plasma clearance rates were reduced upon ligation of renal arteries in rats and rabbits limits the fraction of extrarenal metabolism to 50 and 5%, respectively. This amount of extrarenal metabolism is insufficient to account for the low levels. of drug recovered in the urine of these species.
The biochemical studies which identified DHP-I as the enzyme responsible for THM inactivation were conducted primarily with porcine kidney. The applicability of this finding to those with other species is supported by the identification of a hydrolysis product derived from antibiotic inactivated by porcine enzyme and found by HPLC analyses to be identical to the primary metabolite recovered in rabbit urine. Furthermore, the susceptibility of related carbapenems to purified hog renal DHP-I correlated well with their extent of metabolism in mice. The THM-degrading activity of human kidney homogenates has been found to similarly copurify, with activity against Gly-dh-Phe during enzyme solubilization and partial purification (H. Kropp, unpublished data). It is relevant that DHP-I is reported to have a subcellular localization on the brush border (lumenal face) of the proximal tubular epithelium (C. L. Welch and B. J. Campbell, Fed. Proc. 37:1533, 1978) . It thus has access to antibiotic already cleared from the circulation by glomerular filtration and secretion. Since metabolism occurs only after antibiotic is in transit to the urine, the aforementioned insulation of antibiotic in the systemic circulation from the site of DHP-I in the tubular epithelium is readily explained.
The enzymic cleavage of the beta-lactam ring of THM, MK0787, and related carbapenems is a unique metabolic step in mammalian metabolism. All other naturally occurring carbapenems tested are much more susceptible to DHP-I than to THM. Their higher sensitivity is thought to be a consequence of their acetylated amino-alkylthio side chain. The 5,6-cis-substituted diasteromer of THM produced by enzymatic deacetylation of epithienamycin A was similar to THM in its sensitivity. By contrast, the cis configuration of the hydroxyethyl side chain in this family of structures influences their sensitivity to microbial beta-lactamases (2) . We have also observed significant sensitivity to DHP-I (60% of that of THM) of a penem antibiotic structurally related to THM, the potassium 2-ethyl-thio-6 (1-hydrox- 
